T cell response to tumor antigen

The "T cell response to tumor antigen" encompasses the immunological process by which T cells (primarily CD8+ cytotoxic T cells and CD4+ helper T cells) recognize and respond to peptide fragments (antigens) presented on tumor cells via major histocompatibility complex (MHC) molecules. Tumor antigens include tumor-specific antigens (arising from mutations or viral infection) and tumor-associated antigens (normal proteins aberrantly expressed in cancer). Recognition of these antigens by the T cell receptor (TCR), often with the aid of co-stimulatory signals, leads to T cell activation, proliferation, and targeted destruction of cancerous cells. This response is central to immune surveillance and is the foundation for most cancer immunotherapies including immune checkpoint inhibitors and adoptive T cell therapies. However, it is not itself a single protein, receptor, or druggable molecule, but a complex biological cascade involving multiple cellular and molecular components[1][3][4][5].

Other names

T cell-mediated anti-tumor responseAnti-tumor T cell activityTumor-reactive T cell response

Immune checkpoint inhibition (PD-1/PD-L1, CTLA-4 blockade); Adoptive cell transfer (engineered or expanded T cells); Vaccination to enhance tumor antigen presentation